Patients with previously treated HER2-positive metastatic breast cancer and brain metastases achieved significant intracranial responses with a combination of tucatinib plus trastuzumab and capecitabine, according to findings from a subset of patients in the HER2CLIMB trial.
Results from the CheckMate 9LA suggested that frontline treatment with nivolumab plus ipilimumab combined with 2 cycles of platinum-doublet chemotherapy in patients with metastatic or recurrent non-small cell lung cancer should be considered a new option for this population.
Joyce F. Liu, MD, MPH, discusses findings from a phase 2 study with the Wee1 inhibitor adavosertib in patients with recurrent uterine serous carcinoma.
John Kuruvilla, MD, FRCPC, discusses findings from the phase 3 KEYNOTE-204 trial in Hodgkin lymphoma.
Jesus Berdeja, MD, discusses updated results from the ongoing phase 1b/2 CARTITUDE-1 trial (NCT03548207) in multiple myeloma.
Modest survival benefits were observed in patients with extensive-stage small cell lung cancer who received the combination of pembrolizumab and etoposide plus platinum compared with patients who received EP and placebo.
When added to bortezomib and dexamethasone in patients with multiple myeloma, selinexor, an inhibitor of XPO1-mediated nuclear export, improves progression-free survival and overall response rate and reduces the incidence of peripheral neuropathy.
A phase III study using cediranib and olaparib to treat recurrent platinum-sensitive ovarian cancer did not meet its primary endpoint of progression-free survival but did produce comparable activity to standard of care platinum-based chemotherapy treatment.
Following at least 3 years of follow-up, patients with advanced non-small cell lung cancer and tumor PD-L1 expression ≥ 1% or < 1% experienced durable and long-term efficacy benefits from frontline treatment with nivolumab plus ipilimumab, compared with chemotherapy.
Over half of patients with PIK3CA-positive, HR-positive/HER2-negative advanced breast cancer who had prior treatment with a CDK4/6 inhibitor plus an aromatase inhibitor were alive without disease progression 6 months after starting treatment with alpelisib plus fulvestrant.
The chimeric antigen receptor T-cell therapy, JNJ-4528, continued to demonstrate deep and durable responses in heavily pretreated patients with relapsed/refractory multiple myeloma, according to updated findings from the phase 1b/2 CARTITUDE-1 (NCT03548207) trial.
Belantamab mafodotin in combination with bortezomib (Velcade) and dexamethasone (B-Vd) demonstrated a high rate of clinical benefit and an acceptable safety profile in patients with relapsed or refractory multiple myeloma.
Fam-trastuzumab deruxtecan-nxki demonstrated favorable clinical activity with a high objective response rate and durable responses in patients with HER2-mutated non–small cell lung cancer.
Single agent belantamab mafodotin sustained clinically meaningful deep responses and was well tolerated in patients with heavily pretreated relapsed or refractory multiple myeloma.
Results from the TheraP trial found that in men with metastatic castration resistant prostate cancer who progressed after treatment with docetaxel, 177Lu-PSMA-617 was more active than cabazitaxel.
Zanubrutinib demonstrated a higher complete response or very good partial response rate compared with ibrutinib in patients with Waldenström macroglobulinemia, although the findings were not found to be statistically significant.
Savolitinib showed encouraging efficacy data and an improved safety profile versus sunitinib as a treatment for patients with MET-driven papillary renal cell carcinoma.
Tivozanib demonstrated a significant improvement in progression-free survival when compared with sorafenib, with similar overall survival, in patients with highly relapsed or refractory metastatic renal cell carcinoma.
Nikhil C. Munshi, MD, discusses the role of CAR T-cell therapy in relapsed/refractory multiple myeloma.
Toni K. Choueiri, MD, discusses results of the phase 3 SAVOIR trial evaluating the MET inhibitor savolitinib versus sunitinib in patients with MET-driven papillary renal cell carcinoma.
Melissa L. Johnson, MD, discusses the results of the phase 2 CITYSCAPE trial in PD-L1–positive non–small cell lung cancer (NSCLC).
Sagar Lonial, MD, FACP, discusses the results of the phase 2 DREAMM-2 trial in multiple myeloma.
Patients with chemotherapy-naïve, locally advanced or metastatic non–small cell lung cancer who were treated in the phase 2 CITYSCAPE trial with tiragolumab, an inhibitor of the immunomodulatory receptor TIGIT, plus and anti–PD-L1 agent demonstrated better efficacy versus single-agent checkpoint inhibitor therapy alone.
The combination of next-generation proteasome inhibitor carfilzomib, lenalidomide, and dexamethasone did not show a superiority in progression-free survival in patients with newly diagnosed multiple myeloma when compared with the current standard of care triplet of bortezomib, lenalidomide and dexamethasone.
Data from the long-awaited ECOG-ACRIN E2108 trial showed that surgery and radiation to the tumor does not extend overall survival compared with systemic treatment alone in women with stage IV breast cancer.
Chemotherapy administered within 3 months of a diagnosis of COVID-19 increased the risk of death in patients with thoracic cancer.
The use of real-time comprehensive profiling provides valuable diagnostic information and identifies potential therapeutic targets in adults with malignancies, but this process remains widely underutilized for pediatric patients and represents a significant unmet need.
Gestational trophoblastic tumors (GTTs) that resist chemotherapy can be treated with frontline avelumab, making avelumab the first immunotherapy to show efficacy in treating patients with GTT, according to findings from a cohort of the ongoing phase 2 TROPHIMMUN trial.
Adjuvant treatment with osimertinib demonstrated an 83% reduction in the risk of disease recurrence or death in patients with stage II to IIIA EGFR-mutant non–small cell lung cancer.
Adding avelumab to best supportive care improved the median overall survival by over 7 months in patients with locally advanced or metastatic urothelial carcinoma, according to findings from the phase 3 JAVELIN Bladder 100 study.
